The Cystinuria market growth is driven by factors like increase in the prevalence of Cystinuria, investments in research and development, entry of emerging therapies during the study period 2019-2032.
The Cystinuria market report also offers comprehensive insights into the Cystinuria market size, share, Cystinuria epidemiology, emerging therapies, market drivers and barriers, ongoing clinical trials, key collaboration in the space, market uptake by key therapies and companies actively pushing Cystinuria market size growth forward.
Some of the key highlights from the Cystinuria Market Insights Report:
- Several key pharmaceutical companies, including Revive Therapeutics, Otsuka Pharmaceutical, Eloxx Pharmaceuticals, Travere Therapeutics, Advicenne, and others, are developing novel products to improve the Myelodysplastic Syndrome treatment outlook.
- Promising Cystinuria pipeline therapies in various stages of development include Bucillamine, and others.
- The total Cystinuria market size will include the market size of the potential upcoming therapies and current treatment regimens in the seven major market.
- As per DelveInsight analysis, the Cystinuria market is anticipated to witness growth at a considerable CAGR
Strategise your business goals by understanding market dynamics @ Cystinuria Market Landscape
Cystinuria Overview
Cystinuria is an inherited metabolic disorder characterized by excessive amounts of undissolved cystine in the urine, as well as three chemically similar amino acids: arginine, lysine, and ornithine. Excess cystine in the urine can lead to the formation of crystals and stones (calculi) in the kidney, bladder, and/or urinary tract (ureters). Some people with Cystinuria do not form stones, while others frequently form stones. People with cystinuria excrete abnormally high levels of cystine in the urine. The level of cystine is so high that it remains undissolved in the urine. The amino acids lysine, arginine, and ornithine are also excreted in massive amounts by people with this disorder, but they dissolve more readily in the urine and are not associated with any particular symptoms. Cystinuria is caused by changes (mutations) in the SLC3A1 and SLC7A9 genes. These mutations result in the abnormal transport of cystine in the kidney and this leads to the symptoms of cystinuria. Cystinuria is inherited in an autosomal recessive pattern. Recessive genetic disorders occur when an individual inherits two copies of an altered gene for the same trait, one from each parent. If an individual inherits one normal gene and one gene for the disease, the person will be a carrier for the disease but usually will not show symptoms. People who are carriers of these genes typically have slightly elevated levels of cystine and lysine in the urine.
Do you know the treatment paradigms for different countries? Download our Cystinuria Market Sample Report
Cystinuria Epidemiology Segmentation
DelveInsight’s Cystinuria market report is prepared on the basis of epidemiology model. It offers comprehensive insights to the Cystinuria historical patient pools and forecasted Cystinuria patients. The report provides in-depth data of various subtypes and for the same epidemiology is segmented further. The Cystinuria Market report proffers epidemiological analysis for the study period 2019-32 in the 7MM segmented into:
- Cystinuria Prevalence
- Age-Specific Cystinuria Prevalence
- Gender-Specific Cystinuria Prevalence
- Diagnosed and Treatable Cases of Cystinuria
Visit for more @ Cystinuria Epidemiological Insights
Cystinuria Treatment Market
The Cystinuria market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Cystinuria market trends by analyzing the impact of current Cystinuria therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Cystinuria market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Cystinuria market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Cystinuria market in 7MM is expected to witness a major change in the study period 2019-2032.
Cystinuria Key Companies
- Revive Therapeutics
- Otsuka Pharmaceutical
- Eloxx Pharmaceuticals
- Travere Therapeutics
- Advicenne
Cystinuria Pipeline Therapies
- Bucillamine
Cystinuria Pipeline Analysis: Drug Profile
Bucillamine: Revive Therapeutics
Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine), which has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years, is a cysteine derivative with 2 thiol groups that is 16-fold more potent than NAC as a thiol donor in vivo, giving it vastly superior function in restoring glutathione and therefore greater potential to prevent acute lung injury during influenza infection. The drug is in phase 2 of clinical trials for the treatment of cystinuria.
For more information, visit Cystinuria Market Analysis, Patient Pool, and Emerging Therapies
Scope of the Cystinuria Market Report:
- 11 Years Forecast
- 7MM Coverage
- Descriptive overview of Cystinuria, causes, signs and symptoms, diagnosis, treatment
- Comprehensive insight into Cystinuria epidemiology in the 7MM
- Cystinuria marketed and emerging therapies
- Cystinuria companies
- Cystinuria market drivers and barriers
Key Questions Answered in the Cystinuria Market Report 2032:
- What was the Cystinuria market share distribution in 2019, and how would it appear in 2032?
- What is the total Cystinuria market size and the market size by therapy across the 7MM for the study period (2019-32)?
- What are the important findings from 7MM, and which country will have the greatest Cystinuria market size from 2019-32?
- During the study period (2019-2032), at what CAGR is the Cystinuria market projected to expand at 7MM?
Table of Contents:
1 Cystinuria Market Key Comprehensive Insights
2 Cystinuria Market Report Introduction
3 Competitive Intelligence Analysis for Cystinuria
4 Cystinuria Market Analysis Overview at a Glance
5 Executive Summary of Cystinuria
6 Cystinuria Epidemiology and Market Methodology
7 Cystinuria Epidemiology and Patient Population
8 Cystinuria Patient Journey
9 Cystinuria Treatment Algorithm, Cystinuria Current Treatment, and Medical Practices
10 Key Endpoints in Cystinuria Clinical Trials
11 Cystinuria Marketed Therapies
12 Cystinuria Emerging Therapies
13 Cystinuria: 7 Major Market Analysis
14 Attribute analysis
15 Access and Reimbursement Overview of Cystinuria
16 Cystinuria Market Key Opinion Leaders Reviews
18 Cystinuria Market Drivers
19 Cystinuria Market Barriers
20 SWOT Analysis
21 Disclaimer
22 DelveInsight Capabilities
23 About DelveInsight
Related Reports:
Cystinuria Epidemiology 2032
DelveInsight's "Cystinuria - Epidemiology Forecast to 2032" report delivers an in-depth understanding of the disease, historical and forecasted Cystinuria epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Cystinuria Pipeline 2023
"Cystinuria Pipeline Insights, 2023" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Cystinuria market. A detailed picture of the Cystinuria pipeline landscape is provided, which includes the disease overview and Cystinuria treatment guidelines.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
